Journal: Stem Cell Research & Therapy
Article Title: Pretreatment with growth differentiation factor 15 augments cardioprotection by mesenchymal stem cells in myocardial infarction by improving their survival
doi: 10.1186/s13287-024-04030-6
Figure Lengend Snippet: GDF15 pretreatment augmented paracrine effects of MSCs. A Schematic showing the experiments for assaying the paracrine effect of MSCs with or without GDF15. B Representative images of tube formation in HUVECs treated with DMEM, MSC-CM or GDF15-MSC-CM. Scale bar = 100 μm. C Quantification of tube formation in HUVECs treated with DMEM, MSC-CM or GDF15-MSC-CM. D The concentration of VEGF, EGF and bFGF in MSC-CM and GDF15-MSC-CM was determined by ELISA assay. E Representative images of the apoptotic NCMs treated with DMEM, MSC-CM or GDF15-MSC-CM under SD/H condition. Scale bar = 200 μm. F Quantification of the apoptotic rate of NCMs treated with DMEM, MSC-CM or GDF15-MSC-CM under SD/H condition. Data are expressed as the mean ± SEM. N = 3 biological replicates for each group. * p < 0.05; ** p < 0.01; *** p < 0.001
Article Snippet: MSCs were routinely cultured in DMEM-high glucose (Gibco, 11965084) supplemented 10% fetal bovine serum (FBS, Life Technologies, 16000) with 5 ng/mL endothelial growth factor (EGF, PeproTech, AF-100-15) and 5 ng/mL basic fibroblast growth factor (bFGF, PeproTech, 100-18B) as described previously [ ].
Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay